EDNRB and neoplasm: Our findings are in agreement with recent reports showing that the dual-specific ETAR and ETBR antagonist, Macitentan, has the ability to counteract chronic lymphocytic leukemia cells by inhibiting in vitro migration and proliferation44, as well as tumor growth and metastasis in resistant ovarian cancer xenografts in mice45.